Seres Therapeutics Stock Current Valuation
| 1S9 Stock | EUR 0.80 0.02 2.56% |
Valuation analysis of Seres Therapeutics helps investors to measure Seres Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Seres Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Seres Therapeutics is based on 3 months time horizon. Increasing Seres Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Seres stock is determined by what a typical buyer is willing to pay for full or partial control of Seres Therapeutics. Since Seres Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Seres Stock. However, Seres Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.8 | Real 0.64 | Hype 0.8 | Naive 0.83 |
The real value of Seres Stock, also known as its intrinsic value, is the underlying worth of Seres Therapeutics Company, which is reflected in its stock price. It is based on Seres Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Seres Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Seres Therapeutics helps investors to forecast how Seres stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Seres Therapeutics more accurately as focusing exclusively on Seres Therapeutics' fundamentals will not take into account other important factors: Seres Therapeutics Company Current Valuation Analysis
Seres Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Seres Therapeutics Current Valuation | 582.79 M |
Most of Seres Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Seres Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Seres Therapeutics has a Current Valuation of 582.79 M. This is 95.94% lower than that of the Healthcare sector and 87.45% lower than that of the Biotechnology industry. The current valuation for all Germany stocks is 96.49% higher than that of the company.
Seres Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Seres Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Seres Therapeutics could also be used in its relative valuation, which is a method of valuing Seres Therapeutics by comparing valuation metrics of similar companies.Seres Therapeutics is currently under evaluation in current valuation category among its peers.
Seres Fundamentals
| Return On Equity | -1.9 | |||
| Return On Asset | -0.4 | |||
| Operating Margin | (17.02) % | |||
| Current Valuation | 582.79 M | |||
| Shares Outstanding | 124.59 M | |||
| Shares Owned By Insiders | 6.66 % | |||
| Shares Owned By Institutions | 85.90 % | |||
| Price To Book | 12.02 X | |||
| Price To Sales | 50.23 X | |||
| Revenue | 144.93 M | |||
| Gross Profit | 3.04 M | |||
| EBITDA | (56.72 M) | |||
| Net Income | (65.58 M) | |||
| Cash And Equivalents | 253.62 M | |||
| Cash Per Share | 2.77 X | |||
| Total Debt | 24.64 M | |||
| Debt To Equity | 0.23 % | |||
| Current Ratio | 5.79 X | |||
| Book Value Per Share | 0.54 X | |||
| Cash Flow From Operations | 6.69 M | |||
| Earnings Per Share | (2.18) X | |||
| Target Price | 20.57 | |||
| Number Of Employees | 333 | |||
| Beta | 2.68 | |||
| Market Capitalization | 608.32 M | |||
| Total Asset | 354.86 M | |||
| Z Score | 14.4 | |||
| Net Asset | 354.86 M |
About Seres Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Seres Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Seres Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Seres Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Seres Stock
When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Seres Stock please use our How to Invest in Seres Therapeutics guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.